epiglucan and Streptococcal-Infections

The association of vaccines with immunostimulants such as β-glucan, promote the production of cytokines, competent immune cells and antibodies. However, differences between β-glucan types and trials make it difficult to understand β-glucan's mechanism of action. In this study, three trials were carried out with control and fish fed β-glucan, the first trial occurred at 15 days; the second trial occurred at 30 days when we associated β-glucan and vaccine; and the third trial occurred at 15 days post-challenge with Streptococcus agalactiae in tilapia (O. niloticus) in order to investigate immune-related gene expression in the head kidney and spleen using real-time qPCR. We found increases in HSP70, IL-6, IL-1β, TNF-α, IL-10, Lys and C3 predominantly in the head kidney, except for IgM expression, which prevailed in the spleen, under vaccinated + β-glucan action. This demonstrates the trade-off presented by the head kidney and spleen after immunostimulation in order to produce acquired immunity, as well as an increase in HSP70 expression in vaccinated + β-glucan fish. The results suggest that β-glucan stimulates the immune response through damage-associated molecular patterns (DAMPs) recognition. Therefore, these dynamics of the immune response promote a more robust defense against disease.

Topics: Adaptive Immunity; Adjuvants, Immunologic; Animals; beta-Glucans; Cichlids; Cytokines; Fish Diseases; Fish Proteins; Gene Expression; Head Kidney; HSP70 Heat-Shock Proteins; Muramidase; Signal Transduction; Spleen; Streptococcal Infections; Streptococcal Vaccines; Streptococcus agalactiae

The effects of dietary β-glucan on innate immune responses have been shown in a number of different vertebrate species. However, there is conflicting information about the period of administration (shorter vs. longer), and it is also unclear to what extent β-glucan's effects can be observed post-treatment in fish. Thus, we fed Nile tilapia for 0 (control group; 45 days of control diet), 15 (30 days of control followed by 15 days of β-glucan), 30 (15 days of control followed by 30 days of β-glucan) or 45 days with a diet containing 0.1% of β-glucan (MacroGard®). We evaluated the growth performance at the end of the β-glucan feeding trial and the innate immune function immediately after the feeding trial and 7 and 14 days post-feeding trial. In addition, at day 10 post-feeding trial, we assessed the tilapia's resistance against a bacterial infection. No significant differences were observed in growth performance between the groups; however, fish fed with β-glucan for 30 and 45 days had higher (approx. 8%) relative weight gain compared to the control. Regardless of the administration period, fish fed with β-glucan had higher innate immune responses immediately after the feeding trial such as lysozyme activity in plasma, liver and intestine and respiratory burst compared to the control, and in general these differences were gradually reduced over the withdrawal period (up to 14 days). No differences were observed in the plasma hemolytic activity of the complement or myeloperoxidase activity in plasma or intestine. Moreover, fish from the control group had early mortalities (2 vs. 4-5 days post-infection, respectively) and a lower survival rate (60 vs. 80%, respectively) compared to fish fed with β-glucan for 15 or 30 days, and, interestingly, fish fed for 45 days with β-glucan had no mortality. This study indicates that regardless of the administration period (i.e., 15 up to 45 days), the β-glucan improved the innate immune responses and the tilapia's resistance to disease, and this protection could be observed up to 10 days post-feeding trial, adding in vivo evidence that β-glucan may contribute to a trained innate immunity. Additionally, we showed that a longer period of administration did not cause immunosuppression as previously hypothesized but promoted further growth and immune performance. These findings are relevant to the aquaculture industry and demonstrate that a longer β-glucan feeding protocol may be considered to achieve better results.

Topics: Aeromonas; Animal Feed; Animals; beta-Glucans; Cichlids; Diet; Dietary Supplements; Disease Resistance; Fish Diseases; Gram-Negative Bacterial Infections; Immunity, Innate; Random Allocation; Streptococcal Infections; Streptococcus agalactiae

The role of glucan as a biologically active immunomodulator has been well documented for more than 40 years. However, the wide diversity of β-glucan forms and the extraction process has implications for the benefits of these compounds. Biorigin developed two samples of β-glucans using different biotechnological processes. Thus, in the present study, we fed Nile tilapia (Oreochromis niloticus) diets containing these two β-glucan molecules (BG01 and BG02) for 30 days prior to bacterial infection with Streptococcus agalactiae. The results showed that the different β-glucan samples exhibited biologically differently behaviors, but both increased the resistance against bacterial infection. Specifically, BG01 increased immunostimulation, while BG02 improved growth performance. In summary, these findings confirm the benefits of β-glucans in aquaculture and also provide further evidence of the growth promotion of these compounds.

Topics: Animal Feed; Animals; beta-Glucans; Cichlids; Diet; Dietary Supplements; Fish Diseases; Random Allocation; Streptococcal Infections; Streptococcus agalactiae

β-glucans are widely-known immunostimulants that are profusely used in aquaculture industry. The present study was conducted to evaluate the effect of different in-feed doses of β-1,3/1,6-glucans on the expression of antioxidant and stress-related genes (GST, HSP-70, Vtg), inflammation related genes (Il-8, TNFα, CXC-chemokine and CAS) and adaptive immune-related genes (MHC-IIβ, TLR-7, IgM-H, and Mx) of Oreochromis niloticus challenged and non-challenged with Streptococcus iniae. Six experimental groups were established: non-challenged control (non-supplemented diet), challenged control (non-supplemented diet), non-challenged supplemented with 0.1% β-glucan, challenged supplemented with 0.1% β-glucan, non-challenged supplemented with 0.2% β-glucan and challenged supplemented with 0.2% β-glucan. Fish were fed with β-glucan for 21 days prior challenge and then sampled after 1, 3 and 7 days post-challenge. In non-challenged group, variable effects of the two doses of β-Glucans on the expression of the studied genes were observed; 0.1% induced higher expression of HSP70, CXC chemokine, MHC-IIβ and MX genes. Meanwhile, 0.2% induced better effect on the expression of Vtg, TNF-α, CAS and IgM-H, and almost equal effects of both doses on GST and IL8. However, with the challenged group, 0.2% β-Glucans showed better effect than 0.1% at day one post challenge through significant up-regulation of GST, HSP, IL8, TNF-α, CXC, and MHC-IIβ, meanwhile, the effect of 0.1% was only on the expression of HSP70, MHC-IIβ, and TLR7 at day 3 post challenge. No stimulatory role for both doses of β-Glucans on the expression of almost all genes at day 7 post-challenge. We conclude that both doses of β-glucan can modulate the antioxidant, inflammation, stress and immune-related genes in Nile tilapia, moreover, 0.2% β-Glucans showed better protective effect with Streptococcus iniae challange.

Topics: Adjuvants, Immunologic; Animal Feed; Animals; Antioxidants; beta-Glucans; Cichlids; Diet; Dietary Supplements; Dose-Response Relationship, Drug; Fish Diseases; Immunity, Innate; Inflammation; Streptococcal Infections; Streptococcus iniae; Stress, Physiological